Apomorphine is a powerful dopamine-stimulating medication used to treat sudden “off” episodes in people with advanced Parkinson’s disease. Despite its name, it contains no morphine and has no opioid effects. It works within 7 to 10 minutes, making it the fastest-acting rescue treatment available when Parkinson’s symptoms suddenly break through other medications.
It is the only Parkinson’s drug proven to match the effectiveness of levodopa, the gold-standard treatment, though it works faster and wears off sooner. Its role is not to replace daily Parkinson’s medications but to act as a rapid backup when they fall short.
What “Off” Episodes Are and Why They Matter
People with advanced Parkinson’s disease often take levodopa multiple times a day to control tremor, stiffness, and slowness of movement. Over years of treatment, the drug’s effect becomes less predictable. Sometimes it wears off before the next dose is due (“end-of-dose wearing off”), and sometimes movement simply freezes at unpredictable moments. During these “off” episodes, a person can go from walking and talking normally to being nearly unable to move.
Apomorphine exists specifically for these moments. It is FDA-approved for the acute, intermittent treatment of these off episodes in people with advanced Parkinson’s disease, used alongside their regular medication regimen.
How Apomorphine Works in the Brain
Parkinson’s disease destroys the brain cells that produce dopamine, a chemical messenger essential for smooth, coordinated movement. Levodopa works by giving the brain raw material to make more dopamine. Apomorphine takes a different route: it mimics dopamine directly, binding to the same receptors that dopamine normally activates.
What sets apomorphine apart from other dopamine-mimicking drugs is its range. It activates all five subtypes of dopamine receptor (D1 through D5), which gives it a broad effect that closely resembles natural dopamine signaling. Most other drugs in this class only target a subset of those receptors. This broad activity is likely why apomorphine can match levodopa’s effectiveness when narrower drugs cannot.
How It’s Taken
Apomorphine comes in two forms, each designed for rapid absorption that bypasses the digestive system.
- Subcutaneous injection (Apokyn): A small injection under the skin, similar to an insulin pen. It reaches peak blood levels in about 10 minutes and peak brain levels in about 30 minutes. The clinical effect, relief from the off episode, typically begins within 7 to 10 minutes and lasts 45 to 60 minutes.
- Sublingual film (Kynmobi): A thin strip placed under the tongue that dissolves and absorbs through the mouth’s lining. This was developed because injecting yourself during a period of impaired motor function is understandably difficult. The film avoids that problem while preserving a rapid onset.
There is also a third option used outside the United States since the 1980s: a continuous infusion pump that delivers apomorphine steadily under the skin throughout the day. This approach is designed for people who experience three or more hours of off time daily despite optimized oral medications. In a recent U.S. clinical trial, the pump reduced daily off time by an average of 3 hours and increased “good on” time by a similar amount. By 12 weeks, 68% of patients rated themselves as much or very much improved, and many were able to reduce their daily levodopa dose. These improvements held steady through a full year of follow-up. The pump does not require surgery, which distinguishes it from deep brain stimulation, another advanced Parkinson’s therapy.
Nausea and How It’s Managed
Apomorphine’s biggest practical challenge is nausea. Because it so powerfully stimulates dopamine receptors, it can trigger significant nausea and vomiting, especially during the first few doses. Historically, U.S. prescribing guidelines recommended starting an anti-nausea medication called trimethobenzamide three days before the first apomorphine dose to get ahead of this problem.
However, clinical experience has shown that not everyone needs this pre-treatment. Some people tolerate apomorphine well from the start, and the nausea often fades after the initial period as the body adjusts. Doctors now take a more individualized approach, sometimes skipping the anti-nausea pre-treatment entirely.
Other Side Effects
Beyond nausea, the most common side effects include drowsiness, dizziness, and drops in blood pressure when standing up (which can cause lightheadedness or fainting). Injection-site reactions like redness, swelling, or nodules under the skin are common with long-term subcutaneous use. Some people experience involuntary movements called dyskinesias, particularly if the apomorphine dose is too high relative to their other medications.
Yawning is a surprisingly common early sign that the drug is taking effect and is generally harmless.
A Critical Drug Interaction
One interaction is serious enough to warrant its own mention: apomorphine must not be taken with ondansetron, a widely prescribed anti-nausea drug often given during chemotherapy, after surgery, or for stomach bugs. Combining the two can cause a dangerous drop in blood pressure and loss of consciousness. This is especially important to know because nausea is a common side effect of apomorphine itself, and someone unfamiliar with the interaction might reasonably reach for ondansetron to treat it.
A Surprising History
Apomorphine has one of the more unusual backstories in medicine. It was originally used in the 1800s as a powerful emetic, a drug that induces vomiting, for purposes ranging from emptying the stomach after poisoning to treating respiratory conditions. It was also used in aversive conditioning therapy, where patients were made to vomit after consuming alcohol as a way to treat addiction. Traces of the plant compounds it derives from appear in shamanic rituals from ancient Egypt and Mesoamerica.
In the late 1990s and early 2000s, apomorphine was developed as a treatment for erectile dysfunction, marketed under the brand name Uprima in some countries. Its dopamine-stimulating effects in the brain can trigger arousal pathways, though it was never widely adopted for this purpose. It was the drug’s rediscovery as a Parkinson’s treatment that gave it lasting clinical significance. The injectable form was approved in the U.S. in 2004 and remains one of the few truly fast-acting options for people whose Parkinson’s symptoms break through their daily medication.